Relay Therapeutics, Inc.
RLAY
$12.78
-$0.44-3.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.00M | 7.00M | -- | 677.00K | 7.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.00M | 7.00M | -- | 677.00K | 7.68M |
| Cost of Revenue | 70.56M | 56.34M | 67.89M | 61.47M | 73.81M |
| Gross Profit | -67.56M | -49.34M | -67.89M | -60.80M | -66.13M |
| SG&A Expenses | 11.03M | 13.59M | 12.50M | 13.75M | 18.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.59M | 69.93M | 80.39M | 75.22M | 92.55M |
| Operating Income | -78.59M | -62.93M | -80.39M | -74.55M | -84.87M |
| Income Before Tax | -73.29M | -54.89M | -74.15M | -70.38M | -77.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.29M | -54.89M | -74.15M | -70.38M | -77.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.29M | -54.89M | -74.15M | -70.38M | -77.07M |
| EBIT | -78.59M | -62.93M | -80.39M | -74.55M | -84.87M |
| EBITDA | -78.09M | -62.33M | -79.64M | -73.55M | -83.66M |
| EPS Basic | -0.41 | -0.32 | -0.43 | -0.41 | -0.46 |
| Normalized Basic EPS | -0.25 | -0.21 | -0.27 | -0.25 | -0.28 |
| EPS Diluted | -0.41 | -0.32 | -0.43 | -0.41 | -0.46 |
| Normalized Diluted EPS | -0.25 | -0.21 | -0.27 | -0.25 | -0.28 |
| Average Basic Shares Outstanding | 179.85M | 173.40M | 172.39M | 171.26M | 169.23M |
| Average Diluted Shares Outstanding | 179.85M | 173.40M | 172.39M | 171.26M | 169.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |